Synthetic Antibody Mimics (SyAMs)


Synthetic Antibody Mimics (SyAMs) are bifunctional molecules composed of two active heads attached by a linker in-between. One head, which we call the Immune Binding Terminus (IBT) attaches to specific cells in the immune system. The other head, which we call the Target Binding Terminus (TBT) attaches to the disease cells targeted for destruction. These molecules can be engineered with different IBTs and TBTs giving the platform tremendous versatility to act on a variety of indications.


How SyAMs Work

SyAMs bind tightly with disease cells expressing surface antigens targeted by the molecule's TBT. The molecule's IBT attaches to immune cells already present in the patient's body and the micro-environment of the disease cells. The formation of the ternary complex consisting of the target disease cells, the immune cells, and the SyAM triggers an immune response that leads directly to disease cell destruction.

Platform Advantages

Similar to biologics, SyAMs leverage the patients own immunity in the fight against disease and utilizes mechanisms of action that can be found universally among patients. Unlike biologics, as small molecules, SyAMs have the additional benefit of being inherently non-immunogenic, having greater biological reach and being relatively easy to store, produce, and deliver (non-intravenous modes of delivery).